Clinical Trial Update: Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a phase 1/2 study of defactinib plus pembrolizumab in advanced solid tumors, including non-small cell lung cancer, mesothelioma, and pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Defactinib (defactinib)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: NHS Greater Glasgow and Clyde | Conditions: Carcinoma, Non-small-cell Lung, Mesothelioma | Phase 1, Phase 2 | Status: UNKNOWN